Skip to main content
Premium Trial:

Request an Annual Quote

Luminex to Buy Back Shares

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex said after the close of the market Wednesday that its board of directors has authorized the purchase of up to 1 million shares of the firm's common stock, but not more than $21 million in aggregate purchase price.

Luminex said that the repurchase program will run through November 2011. The purchases will be made from time to time on the open market or through privately negotiated transactions. Luminex currently has 42.3 million shares outstanding.

"We believe that the stock repurchase program announced today represents an appropriate and strategic use of the company's cash, while retaining sufficient flexibility to fund future expenditures, including acquisition, licensing, and partnership opportunities as well as investments in research and development," Luminex President and CEO Patrick Balthrop said in a statement.

As of Sept. 30, Luminex had $80.2 million in cash, cash equivalents, and restricted cash, plus $27.9 million in short-term investments.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.